Study establishes Ku70’s role in tumor suppression, showing that reduced expression or mutations in this DNA repair protein significantly increase intestinal cancer risk.
Sanofi shelves four assets, including mid-stage dwarfism candidate
Sanofi is deprioritizing a mid-stage treatment for a form of dwarfism and culling three other early-stage studies. The French pharma deprioritized a Phase 2 drug
July 26, 2024